Page last updated: 2024-10-25

citalopram and Dysthymia

citalopram has been researched along with Dysthymia in 11 studies

Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.

Research Excerpts

ExcerptRelevanceReference
"Numerous studies have assessed the acute efficacy of antidepressants, including selective serotonin reuptake inhibitors, in treating dysthymic disorder; however, escitalopram, the S-enantiomer of citalopram, has not been studied."9.14Escitalopram versus placebo in the treatment of dysthymic disorder. ( Arnaout, B; Batchelder, ST; Benga, I; Gangure, D; Hellerstein, DJ; Hyler, S; Toba, C, 2010)
"This study aimed to provide preliminary data on the tolerability and effectiveness of citalopram for patients with dysthymic disorder."9.11Citalopram in the treatment of dysthymic disorder. ( Batchelder, S; Clark, J; Gangure, D; Hellerstein, DJ; Hyler, S; Kreditor, D; Miozzo, R, 2004)
"We studied 15 patients with dysthymic disorder with open-label citalopram."9.10Dysthymic disorder: treatment with citalopram. ( Bea, C; Budech, CB; Dunner, DL; Friedman, SD; Hendricksen, HE, 2002)
"Relatively treatment-naive depressed outpatients (with DSM-IV diagnoses of major depressive disorder, dysthymic disorder, or depression not otherwise specified) were initially treated with a combination of escitalopram (ESC) plus bupropion (BUP), using rapid dose escalation to ESC 40 mg/day plus BUP 400 to 450 mg/day by study day 15 in an open-label, 8-week study."5.14Does dual antidepressant therapy as initial treatment hasten and increase remission from depression? ( Deliyannides, RA; McGrath, PJ; Quitkin, FM; Stewart, JW, 2009)
"Numerous studies have assessed the acute efficacy of antidepressants, including selective serotonin reuptake inhibitors, in treating dysthymic disorder; however, escitalopram, the S-enantiomer of citalopram, has not been studied."5.14Escitalopram versus placebo in the treatment of dysthymic disorder. ( Arnaout, B; Batchelder, ST; Benga, I; Gangure, D; Hellerstein, DJ; Hyler, S; Toba, C, 2010)
"This study aimed to provide preliminary data on the tolerability and effectiveness of citalopram for patients with dysthymic disorder."5.11Citalopram in the treatment of dysthymic disorder. ( Batchelder, S; Clark, J; Gangure, D; Hellerstein, DJ; Hyler, S; Kreditor, D; Miozzo, R, 2004)
"We studied 15 patients with dysthymic disorder with open-label citalopram."5.10Dysthymic disorder: treatment with citalopram. ( Bea, C; Budech, CB; Dunner, DL; Friedman, SD; Hendricksen, HE, 2002)
"The treatment of dysthymia in itself poses a problem in the everyday psychiatric practice and it can be further hindered when accompanied by pronounced personality traits (which are indicative of disorder)."1.37Allergic reactions--outcome of sertraline and escitalopram treatments. ( Dadić-Hero, E; Grahovac, T; Graovac, M; Palijan, TZ; Ružić, K; Sepić-Grahovac, D, 2011)

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (54.55)29.6817
2010's5 (45.45)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Vidyasagar, S1
Rao, K1
Verma, M1
Tripuraneni, AD1
Patil, N1
Bhattacharjee, D1
Ho, PS1
Yeh, YW1
Huang, SY1
Liang, CS1
Amitai, M1
Kronenberg, S1
Carmel, M1
Michaelovsky, E1
Frisch, A1
Brent, D1
Apter, A1
Chen, A1
Weizman, A1
Fennig, S1
Lehto, SM1
Tolmunen, T1
Kuikka, J1
Valkonen-Korhonen, M1
Joensuu, M1
Saarinen, PI1
Vanninen, R1
Ahola, P1
Tiihonen, J1
Lehtonen, J1
Stewart, JW1
McGrath, PJ1
Deliyannides, RA1
Quitkin, FM1
Dadić-Hero, E1
Ružić, K1
Grahovac, T1
Graovac, M1
Palijan, TZ1
Sepić-Grahovac, D1
Hellerstein, DJ2
Batchelder, ST1
Hyler, S2
Arnaout, B1
Toba, C1
Benga, I1
Gangure, D2
Batchelder, S1
Miozzo, R1
Kreditor, D1
Clark, J1
Bastiaens, L1
Rosenberg, C1
Lauritzen, L1
Brix, J1
Jørgensen, JB1
Kofod, P1
Bayer, LB1
Dunner, DL1
Hendricksen, HE1
Bea, C1
Budech, CB1
Friedman, SD1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Combined Escitalopram/Bupropion as First Line Treatment for Depression, a Replication.[NCT00296712]Phase 455 participants (Actual)Interventional2005-02-28Completed
Double-Blind Placebo-Controlled Study of Escitalopram in the Treatment of Dysthymic Disorder[NCT00220701]Phase 436 participants (Actual)Interventional2002-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Beck Depression Inventory (BDI)

21 item patient rated assessment of depression symptoms, with item scores ranging from 0 to 3. Total BDI scores can range from 0 to 63, with higher scores indicating worse depression. (NCT00220701)
Timeframe: Baseline

Interventionunits on a scale (Mean)
Escitalopram15.00
Placebo16.25

Beck Depression Inventory (BDI)

21 item patient rated assessment of depression symptoms, with item scores ranging from 0 to 3. Total BDI scores can range from 0 to 63, with higher scores indicating worse depression. (NCT00220701)
Timeframe: Week 12

Interventionunits on a scale (Mean)
Escitalopram6.76
Placebo10.00

Clinical Global Impressions - Severity (CGI-S)

Clinician rated severity, score on CGI-S scale ranging from 1 (no pathology) to 7 (extreme pathology) (NCT00220701)
Timeframe: Baseline

Interventionunits on a scale (Mean)
Escitalopram4.06
Placebo4.06

Clinical Global Impressions - Severity (CGI-S)

Clinician rated severity, score on CGI-S scale ranging from 1 (no pathology) to 7 (extreme pathology) (NCT00220701)
Timeframe: Week 12

Interventionunits on a scale (Mean)
Escitalopram2.35
Placebo3.41

Hamilton-Depression Rating Scale (HDRS-24 Items)

Clinician rated measure of depression, mean score; This study used the 24 item version of the Hamilton Depression Rating Scale; item scores range from 0 to 4 on some items, 0 to 2 or 0 to 3 on other items; range of total score = 0 to 75, with higher score indicating worse depression Response (>50% decrease) Remission (score<=7) (NCT00220701)
Timeframe: Baseline

Interventionunits on a scale (Mean)
Escitalopram22.82
Placebo24.41

Hamilton-Depression Rating Scale (HDRS-24 Items)

Clinician rated measure of depression, mean score; This study used the 24 item version of the Hamilton Depression Rating Scale; item scores range from 0 to 4 on some items, 0 to 2 or 0 to 3 on other items; range of total score = 0 to 75, with higher score indicating worse depression Response (>50% decrease) Remission (score<=7) (NCT00220701)
Timeframe: Week 12

Interventionunits on a scale (Mean)
Escitalopram10.88
Placebo16.41

Trials

6 trials available for citalopram and Dysthymia

ArticleYear
Pharmacogenetics of citalopram-related side effects in children with depression and/or anxiety disorders.
    Journal of neural transmission (Vienna, Austria : 1996), 2016, Volume: 123, Issue:11

    Topics: Adolescent; Anxiety Disorders; Child; Citalopram; Depressive Disorder, Major; Dysthymic Disorder; Fe

2016
Does dual antidepressant therapy as initial treatment hasten and increase remission from depression?
    Journal of psychiatric practice, 2009, Volume: 15, Issue:5

    Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Citalopram; Depressive Disorder; Depress

2009
Escitalopram versus placebo in the treatment of dysthymic disorder.
    International clinical psychopharmacology, 2010, Volume: 25, Issue:3

    Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Dose-Response Relationship, Drug; Doubl

2010
Citalopram in the treatment of dysthymic disorder.
    International clinical psychopharmacology, 2004, Volume: 19, Issue:3

    Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Cognition; Dose-Response Relationship,

2004
Citalopram versus amitriptyline in elderly depressed patients with or without mild cognitive dysfunction: a danish multicentre trial in general practice.
    Psychopharmacology bulletin, 2007, Volume: 40, Issue:1

    Topics: Aged; Aged, 80 and over; Amitriptyline; Antidepressive Agents, Second-Generation; Antidepressive Age

2007
Dysthymic disorder: treatment with citalopram.
    Depression and anxiety, 2002, Volume: 15, Issue:1

    Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Double-Blind Method; Dysthymic Disorder

2002

Other Studies

5 other studies available for citalopram and Dysthymia

ArticleYear
Escitalopram Induced SIADH in an Elderly Female: A Case Study.
    Psychopharmacology bulletin, 2017, 09-15, Volume: 47, Issue:4

    Topics: Citalopram; Dysthymic Disorder; Female; Humans; Hyponatremia; Inappropriate ADH Syndrome; Middle Age

2017
A shift toward T helper 2 responses and an increase in modulators of innate immunity in depressed patients treated with escitalopram.
    Psychoneuroendocrinology, 2015, Volume: 53

    Topics: Adult; Antidepressive Agents; Case-Control Studies; Citalopram; Cytokines; Depressive Disorder; Depr

2015
Midbrain serotonin and striatum dopamine transporter binding in double depression: a one-year follow-up study.
    Neuroscience letters, 2008, Aug-29, Volume: 441, Issue:3

    Topics: Adult; Binding, Competitive; Biomarkers; Citalopram; Corpus Striatum; Depressive Disorder, Major; Di

2008
Allergic reactions--outcome of sertraline and escitalopram treatments.
    Psychiatria Danubina, 2011, Volume: 23, Issue:1

    Topics: Adult; Angioedema; Antidepressive Agents; Citalopram; Combined Modality Therapy; Drug Eruptions; Dru

2011
Adolescents' response to antidepressant treatment in a community mental health center.
    Community mental health journal, 2005, Volume: 41, Issue:1

    Topics: Adolescent; Adolescent Psychiatry; Algorithms; Antidepressive Agents; Child; Child Psychiatry; Cital

2005